Literature DB >> 23958941

The antidepressant-like action of mGlu5 receptor antagonist, MTEP, in the tail suspension test in mice is serotonin dependent.

Agnieszka Pałucha-Poniewiera, Piotr Brański, Joanna M Wierońska, Katarzyna Stachowicz, Anna Sławińska, Andrzej Pilc.   

Abstract

RATIONALE: Numerous studies indicate the potential antidepressant actions of several mGlu5 receptor antagonists, including 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine (MTEP). The explanation for the mechanism of these effects might be a key step in finding new antidepressant drugs (AD).
OBJECTIVES: The aim of the present study was to investigate the possible role of the serotonergic system in the antidepressant-like activity of MTEP in the tail suspension test (TST) in C57BL/6J mice, using selected antagonists of serotonergic receptors and by applying two different methods of serotonin (5-HT) depletion.
RESULTS: The results of our studies showed that the mGlu5 receptor antagonist, MTEP, similar to the fluoxetine used as reference AD, did not induce antidepressant-like effects in mice pretreated with tryptophan hydroxylase inhibitor, parachlorophenylalanine. On the other hand, MTEP worked as a potential AD in the TST in mice fed on a tryptophan-free (TRP-free) diet for 3 weeks. However, fluoxetine, which was used as a reference control was also active in this experiment, suggesting that a TRP-free diet was not sufficiently effective in reducing the 5-HT level. Furthermore, we showed that the 5HT2A/2C antagonist, ritanserin, yet not the 5-HT1A antagonist, WAY100635, 5HT1B antagonist, SB224289 or 5HT4 antagonist, GR125487, reversed the antidepressant-like effects of MTEP in the TST. Finally, a sub-effective dose ofMTEP coadministered with a sub-effective dose of citalopram induced an antidepressant-like effect in the TST in mice.
CONCLUSION: The results of our studies suggest the involvement of serotonergic system activation in the antidepressant-like effects of the mGlu5 antagonist, MTEP, in the TST in mice.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23958941     DOI: 10.1007/s00213-013-3206-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  46 in total

1.  MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity.

Authors:  Shigeyuki Chaki; Ryoko Yoshikawa; Shiho Hirota; Toshiharu Shimazaki; Maoko Maeda; Naoya Kawashima; Takao Yoshimizu; Akito Yasuhara; Kazunari Sakagami; Shigeru Okuyama; Shigetada Nakanishi; Atsuro Nakazato
Journal:  Neuropharmacology       Date:  2004-03       Impact factor: 5.250

2.  Modulation of the neuronal dopamine transporter activity by the metabotropic glutamate receptor mGluR5 in rat striatal synaptosomes through phosphorylation mediated processes.

Authors:  G Page; M Peeters; M Najimi; J M Maloteaux; E Hermans
Journal:  J Neurochem       Date:  2001-03       Impact factor: 5.372

3.  Simultaneous alterations of brain and plasma serotonin concentrations and liver cytochrome P450 in rats fed on a tryptophan-free diet.

Authors:  Marta Kot; Andrzej Pilc; Władysława A Daniel
Journal:  Pharmacol Res       Date:  2012-06-27       Impact factor: 7.658

4.  The antidepressant-like action of metabotropic glutamate 7 receptor agonist N,N'-bis(diphenylmethyl)-1,2-ethanediamine (AMN082) is serotonin-dependent.

Authors:  Agnieszka Pałucha-Poniewiera; Piotr Brański; Tomasz Lenda; Andrzej Pilc
Journal:  J Pharmacol Exp Ther       Date:  2010-06-18       Impact factor: 4.030

5.  Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression.

Authors:  Lobna Ibrahim; Nancy Diazgranados; David A Luckenbaugh; Rodrigo Machado-Vieira; Jacqueline Baumann; Alan G Mallinger; Carlos A Zarate
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-04-03       Impact factor: 5.067

6.  Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.

Authors:  G J Marek; R A Wright; D D Schoepp; J A Monn; G K Aghajanian
Journal:  J Pharmacol Exp Ther       Date:  2000-01       Impact factor: 4.030

7.  Anxiolytic-like action of MTEP expressed in the conflict drinking Vogel test in rats is serotonin dependent.

Authors:  K Stachowicz; K Gołembiowska; M Sowa; G Nowak; E Chojnacka-Wójcik; A Pilc
Journal:  Neuropharmacology       Date:  2007-08-14       Impact factor: 5.250

8.  On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039.

Authors:  Agnieszka Pałucha-Poniewiera; Joanna M Wierońska; Piotr Brański; Katarzyna Stachowicz; Shigeyuki Chaki; Andrzej Pilc
Journal:  Psychopharmacology (Berl)       Date:  2010-08-12       Impact factor: 4.530

9.  Identification of a serotonin/glutamate receptor complex implicated in psychosis.

Authors:  Javier González-Maeso; Rosalind L Ang; Tony Yuen; Pokman Chan; Noelia V Weisstaub; Juan F López-Giménez; Mingming Zhou; Yuuya Okawa; Luis F Callado; Graeme Milligan; Jay A Gingrich; Marta Filizola; J Javier Meana; Stuart C Sealfon
Journal:  Nature       Date:  2008-02-24       Impact factor: 49.962

10.  The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety.

Authors:  Chris S Busse; Jesse Brodkin; David Tattersall; Jeffery J Anderson; Noelle Warren; Lida Tehrani; Linda J Bristow; Mark A Varney; Nicholas D P Cosford
Journal:  Neuropsychopharmacology       Date:  2004-11       Impact factor: 7.853

View more
  6 in total

1.  Homeostatic cAMP regulation by the RGS7 complex controls depression-related behaviors.

Authors:  Cesare Orlandi; Laurie P Sutton; Brian S Muntean; Chenghui Song; Kirill A Martemyanov
Journal:  Neuropsychopharmacology       Date:  2018-10-11       Impact factor: 7.853

Review 2.  Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants.

Authors:  Shigeyuki Chaki; Kenichi Fukumoto
Journal:  Pharmaceuticals (Basel)       Date:  2015-09-17

3.  Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice.

Authors:  Ewa Poleszak; Weronika Stasiuk; Aleksandra Szopa; Elżbieta Wyska; Anna Serefko; Anna Oniszczuk; Sylwia Wośko; Katarzyna Świąder; Piotr Wlaź
Journal:  Metab Brain Dis       Date:  2016-02-29       Impact factor: 3.584

Review 4.  Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders?

Authors:  Gustavo A Angarita; Hasti Hadizadeh; Ignacio Cerdena; Marc N Potenza
Journal:  Expert Opin Pharmacother       Date:  2021-06-23       Impact factor: 4.103

Review 5.  The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders.

Authors:  Daniel Peterlik; Peter J Flor; Nicole Uschold-Schmidt
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

Review 6.  Group 1 Metabotropic Glutamate Receptors in Neurological and Psychiatric Diseases: Mechanisms and Prospective.

Authors:  Li-Da Su; Na Wang; Junhai Han; Ying Shen
Journal:  Neuroscientist       Date:  2021-06-04       Impact factor: 7.235

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.